Mycophenolate in scleroderma-associated interstitial lung disease: Real-world data from rheumatology and pulmonology clinics in South Asia

Abstract

Introduction:

There is a paucity of real-world data on mycophenolate mofetil/mycophenolate sodium in systemic sclerosis-related interstitial lung disease.

Aim:

To study the efficacy of mycophenolate mofetil/ mycophenolate sodium in systemic sclerosis-related interstitial lung disease.

Methods:

In this single-centre study, clinical, laboratory and imaging details of consecutive patients with systemic sclerosis-related interstitial lung disease receiving mycophenolate mofetil/mycophenolate sodium from rheumatology and pulmonology clinics between January 2008 and March 2017 were retrospectively retrieved. The change in percentage of predicted normal forced vital capacity at last follow-up visit as compared with baseline was studied. In addition, high-resolution computed tomography scans at baseline and 2-year follow-up visit were scored as either stable/improved or worsened by experienced thoracic radiologists blinded to the clinical details of patients.

Results:

Altogether, 88 patients (85.2% females) with mean age (SD) of 33.8 years (± 11.3) and median (interquartile range) duration of disease since non-Raynaud’s symptoms of 36 months (13.5–60) were studied. Diffuse systemic sclerosis comprised 85.2% of them. The mean baseline forced vital capacity was 61.2 ± 17.9% and median scores for ground glass opacities and fibrosis in high-resolution computed tomography were 0.5 (0–1.3) and 1 (0–1.3), respectively. At a median follow-up duration of 30 months (interquartile range = 16.5–49), the percentage of forced vital capacity improved by 1.8% (–3.82 to 9.07) as compared with baseline visit (p = 0.02). In the 2-year follow-up, the ground glass opacity and fibrosis scores in high-resolution computed tomography improved in 17.3% and 7.7% of patients and stabilized in 63.5% and 78.8% patients, respectively.

Conclusion:

Mycophenolate mofetil/mycophenolate sodium was efficacious in improving /stabilizing forced vital capacity irrespective of the baseline high-resolution computed tomography lung scores in our patients with systemic sclerosis-related interstitial lung disease during the ⩾ 2-year follow-up period.

Keywords

Scleroderma-ILD mycophenolate outcomes

Get full access to this article

View all access options for this article.

References

Suliman

Dobrota

Huscher

, et al. Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 2015; 67(12): 3256–3261.

Steele

Hudson

, et al. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res 2012; 64(4): 519.

Janardana

Nair

Surin

, et al. Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma-do South Asians have a more aggressive disease? Clin Rheumatol 2019; 38: 3179–3187.

Steen

Medsger

TA.

Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66(7): 940–944.

Tyndall

Bannert

Vonk

, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis 2010; 69(10): 1809–1815.

Tashkin

Roth

Clements

, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4(9): 708–719.

Tzouvelekis

Galanopoulos

Bouros

, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med 2012; 2012: 143637.

Shenoy

Bavaliya

Sashidharan

, et al. Cyclophospha-mide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther 2016; 18(1): 123.

LeRoy

Black

Fleischmajer

, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15(2): 202–205.

10.

Miller

Hankinson

Brusasco

, et al. ATS/ERS task force. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338.

11.

Collard

Loyd

King

Jr , et al. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med 2007; 101(9): 2011–2016.

12.

Kazerooni

Martinez

Flint

, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin- section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169(4): 977–983.

13.

Goh

Desai

Veeraraghavan

, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 124854.

14.

Goldin

Elashoff

Kim

, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009; 136(5): 1333–1340.

15.

Khanna

Furst

Hays

, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006; 65(10): 1325–1329.

16.

World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310(20): 2191–2194.

17.

Kafaja

Clements

Wilhalme

, et al. Reliability and minimal clinically important differences of FVC. Results from the scleroderma lung studies (SLS-I and SLS-II). Am J Respir Crit Care Med 2018; 197: 644–652.

18.

Tashkin

Elashoff

Clements

, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354(25): 2655–2666.

19.

Roth

Tseng

Clements

, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011; 63(9): 2797–2808.

20.

Khanna

Tseng

Farmani

, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63(10): 3078–3085.

21.

Goh

Hoyles

Denton

, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017; 69(8): 1670–1678.

22.

Katzenstein

Fiorelli

RF.

Non-specific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18: 136–147.